TrialClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial.

Carlos Brites et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.